Kunjin replicon based vaccines for HIV [ 2004 - 2006 ]

Research Grant

Researchers: Prof Andreas Suhrbier (Principal investigator) ,  A/Pr David Harrich ,  Prof Alexander Khromykh

Brief description In recent years it has become clear that certain white blood cells called CD8+ T lymphocytes or killer T cells are required to protect people against HIV. Unfortunately, current vaccines that produce or anti-HIV CD8 T cells only produce effective T cells for a short period. In this project we intend to test a novel vaccine vector called a Kunjin replicon, which promises to persistently produce or maintain effective T cells because the vaccine itself persists and continually immunises for extended periods. We intend to test the ability of this vaccine to persist and persistently produce effective CD8 T cells not only systemically in the blood system but also at mucosal surfaces, where HIV usually gains entry during sexual intercourse.

Funding Amount $AUD 343,875.00

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant